MERCK-MILLIPORE
15.9.2014 08:01:31 CEST | Business Wire | Pressemeddelelse
Merck Millipore, the Life Science division of Merck, announced it has received two R&D Magazine 100 Awards for innovative products released to market in 2014. The 52nd Annual R&D Awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
“A key component of our strategy is to offer the highest quality and most innovative products. Recognition for two R&D Magazine awards exemplifies our technical expertise and leadership in providing differentiated solutions to a broad range of customers across the life science industry,” said Udit Batra, President and Chief Executive Officer of Merck Millipore. “In 2013, Merck Millipore invested €160 million in R&D activities, and we will continue to support efforts to drive future advancements in our portfolio of offerings. We are most appreciative of those employees who have dedicated their careers to furthering scientific advancement in these fields.”
The Merck Millipore products that were recognized are:
- The SmartFlare™ detection reagent is a novel probe capable of detecting specific mRNAs and miRNAs in live, intact cells. This technology allows for carrier-free cellular endocytosis of the reagent, followed by detection and relative quantitative analysis of RNA levels. Because the reagent leaves the cell after the detection event, the same sample can be used for any downstream analysis, meaning you can assess multiple biomarkers or downstream functionalities in the same cells.
- Clarisolve ® depth filters are specifically tuned to the particle size distribution of various pretreatment methodologies enabling the fastest and most efficient way to clarify high-density streams and easily transfer processes from upstream to downstream without the use of centrifugation. Clarisolve depth filters were designed for high cell density/titer mammalian cell culture feed streams for mAb production. There has also been early success in microbial and vaccine applications.
With nearly 800 employees focused on R&D, Merck Millipore is working with customers to develop innovative solutions for the research, development and production of biopharmaceuticals and biotech processes worldwide.
Widely regarded as the “Oscars of Invention”, the R&D 100 Awards identify and celebrate the top technology products of the year. Past winners have included sophisticated testing equipment, innovative new materials, chemistry breakthroughs, biomedical products, consumer items, and high-energy physics. The R&D 100 Awards spans industry, academia, and government-sponsored research.
The winners of the R&D 100 Awards are selected by an independent judging panel and the editors of R&D Magazine.
About Merck Millipore
Merck Millipore is the Life Science
division of Merck and offers a broad range of innovative, performance
products, services and business relationships that enable our customers’
success in research, development and production of biotech and
pharmaceutical drug therapies. Through dedicated collaboration on new
scientific and engineering insights, and as one of the top three R&D
investors in the Life Science Tools industry, Merck Millipore serves as
a strategic partner to customers and helps advance the promise of life
science. Headquartered in Billerica, Massachusetts, the division has
around 10,000 employees, operations in 66 countries and 2013 revenues of
€2.6 billion Merck Millipore operates as EMD Millipore in the U.S. and
Canada.
About Merck
Merck is a leading company for innovative and
top-quality high-tech products in the pharmaceutical and chemical
sectors. With its four divisions Merck Serono, Consumer Health,
Performance Materials and Merck Millipore, Merck generated total
revenues of €11.1 billion in 2013. Around 39,000 Merck employees work in
66 countries to improve the quality of life for patients, to further the
success of customers and to help meet global challenges. Merck is the
world’s oldest pharmaceutical and chemical company – since 1668, the
company has stood for innovation, business success and responsible
entrepreneurship. Holding an approximately 70 percent interest, the
founding family remains the majority owner of the company to this day.
Merck, Darmstadt, Germany is holding the global rights to the Merck name
and brand. The only exceptions are Canada and the United States, where
the company is known as EMD.
About R&D Magazine
Since its founding in 1959 as Industrial
Research
, R&D Magazine
has served research
scientists, engineers and technical staff at laboratories around the
world, providing timely, informative news and useful technical articles
that broaden readers’ knowledge of the research and development industry
and improve the quality of their work. R&D Magazine
is a
publication of Advantage Business Media (www.advantagebusinessmedia.com
).
Contact:
Susan Alesina, 978-715-4622
susan.alesina@emdmillipore.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum